{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046955","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.604820+00:00","generated_at":"2026-05-22T00:43:14.713389+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression","bullets":["Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.","Positive interim Phase 1b APG808 results: FeNO suppression 53% max, sustained 50% at 12 weeks; well tolerated.","Phase 2 APEX trial of APG777 advancing; interim Part A 16-week data expected mid-2025.","First patient dosed in Phase 1b APG777 asthma trial; readout expected 1H 2026.","APG279 (APG777+APG990) head-to-head vs DUPIXENT on track to initiate in 2025; readout 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046955","json":"https://secwatch.observer/filing/0001104659-25-046955.json","markdown":"https://secwatch.observer/filing/0001104659-25-046955.md","text":"https://secwatch.observer/filing/0001104659-25-046955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/0001104659-25-046955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/tm2514695d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:43:14.713389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}